Asia
Grape King Bio Clarifies Report Projecting NT$10 Billion Revenue in 2026
Grape King Bio (TPE:1707) clarified a Commercial Times report stating the company is targeting NT$10 billion in annual revenue, noting that the figure was based solely on projections from institutional investors and not on company guidance.The biotech company said its annual revenue had already exceeded NT$10 billion in 2022, according to a Tuesday filing with the Taiwan Exchange.Grape King Bio said investors should refer to its disclosures on the Market Observation Post System for financial information.
TPE:1707
